<DOC>
	<DOCNO>NCT00869115</DOCNO>
	<brief_summary>This study explore potential drug-drug interaction istaroxime digoxin patient stable CHF chronic oral digoxin treatment .</brief_summary>
	<brief_title>Phase I Interaction Study Istaroxime Digoxin Subjects With Stable Heart Failure</brief_title>
	<detailed_description>This single center , randomize , double blind , placebo control , escalate dose phase I interaction study . The three dose level istaroxime placebo randomize sequentially three cohort ( I III ) 16 patient ( 12 patient istaroxime 4 patient placebo ) . Digoxin administer non blind patient , daily morning standardize breakfast , continue previously personalize dosage schedule screen period , treatment period , post treatment period follow period . Prior accrual cohort II III , Data Monitoring Committee ( DMC ) advise continuation next istaroxime dose , base predetermine safety review . This 37 day study include screening period ( Days -21 -1 ) , treatment period ( Day 1 ) , post treatment period ( Days 2-4 ) , follow period ( include one patient visit Day 14 ) . Patients confine phase I research center Day -2 Day 4 .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<criteria>Main screen inclusion criterion : Signed informed consent ; Male female patient ≥18 year ; Female patient childbearing potential must pregnant ; Chronic stable cardiac function impairment ( change heart failure medication last 3 month without dosage adjustment last 4 week ) ; Systolic blood pressure ( SBP ) ≥ 90 mmHg ≤ 140 mmHg ; LVEF ≤ 35 % method ( perform screening measure within last 12 month ) ; Chronic treatment ( i.e . daily dose without interruption ) oral digoxin start least 3 month prior study entry without concomitant administration positive inotropic drug ; Main screen exclusion criterion : Need current intermittent intravenous positive inotrope administration within precede 6 month , hemodynamic support device ; Acute coronary syndrome within past 3 month ; Coronary artery bypass graft percutaneous coronary intervention within past 3 month ; Stroke within past 6 month ; Atrial fibrillation uncontrolled heart rate ( HR ) ( &gt; 100 beat per minute [ bpm ] ) ; Significant arrhythmia second third degree atrioventricular block ; Valvular disease primary cause HF ; Significant ECG abnormality assess appropriately qualified physician investigator include QTcF &gt; 450 ; Positive test Human Immunodeficiency Virus ( HIV ) , Hepatitis B and/or Hepatitis C ; Main randomization exclusion criterion : HR &gt; 100 bpm &lt; 50 bpm ; Serum potassium &gt; 5.3 mmol/L &lt; 3.8 mmol/L magnesium &gt; 1.1 mmol/L &lt; 0.6 mmol/L , TN I &gt; ULN .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Digoxin</keyword>
	<keyword>Inotropes</keyword>
	<keyword>Lusitropic agent</keyword>
	<keyword>Istaroxime</keyword>
	<keyword>Debio 0614</keyword>
</DOC>